

AD _____

GRANT NUMBER DAMD17-96-1-6281

TITLE: Expression of Novel Steroid/Receptors in Mammary
Development: Peroxisome Proliferator Activated Receptors

PRINCIPAL INVESTIGATOR: Jeffrey M. Gimble, M.D., Ph.D.

CONTRACTING ORGANIZATION: Oklahoma Medical Research Foundation
Oklahoma City, OK 73104

REPORT DATE: August 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

19971218 028

DTIC QUALITY INSPECTED 4

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED	
	August 1997	Annual (1 Aug 96 - 31 Jul 97)	
4. TITLE AND SUBTITLE Expression of Novel Steroid/Receptors in Mammary Development: Peroxisome Proliferator Activated Receptors		5. FUNDING NUMBERS DAMD17-96-1-6281	
6. AUTHOR(S) Jeffrey M. Gimble, M.D., Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Oklahoma Medical Research Foundation Oklahoma City, OK 73104		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012		10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 See introduction			
14. SUBJECT TERMS Breast Cancer		15. NUMBER OF PAGES 15	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Jeff Sable
PI - Signature

8/13/97
Date

TABLE OF CONTENTS

SECTION	PAGE
FRONT COVER	1
STANDARD FORM 298	2
FOREWORD	3
TABLE OF CONTENTS	4
BODY	5 - 8
CONCLUSIONS	9
REFERENCES	10
APPENDICES	11 - 15

INTRODUCTION

Subject: This research will determine the expression pattern of a novel class of nuclear hormone receptors, the peroxisome proliferator activated receptors (PPARs), during mammary gland development in rodent models.

Purpose: The long-term goal of these studies is to determine if PPARs represent a potential target for the treatment of mammary tumors.

Scope of the research: The studies in this IDEA grant are limited to murine and rat models. They combine immunohistochemical and molecular biological approaches to examine the expression profile the different PPAR genes in mammary tissues from virgin, pregnant, and lactating mice and in rat mammary tumors induced by 7,12-dimethylbenzanthracene (DMBA).

Background of previous work: The epithelial cells of the mammary gland proliferate and mature in close proximity with the stromal adipocytes and fibroblasts. Stromal cells regulate the growth and development of the terminal end bud epithelial cells into alveolae and ducts through direct cell-cell interactions and the release of cytokines. The adipocytes of the mammary fat pad are critical for these epithelial events; transplanted mammary epithelial cells will only grow in the presence of adipose tissue [1,2]. This implies that mechanisms controlling adipogenesis impact on the physiology and pathology of the mammary gland in rodents and humans. Previous studies on bone marrow stromal cells and other pre-adipocyte models have demonstrated that the PPAR nuclear hormone receptors regulate adipocyte differentiation and the transcription of adipocyte-specific genes [3-5]. The PPAR ligands include the thiazolidinediones, used as oral anti-diabetic agents, and indomethacin, an anti-inflammatory drug [6-8]. The presence of these PPAR ligands induces pre-adipocyte stromal cells to differentiate into adipocytes *in vitro*. These compounds have potential relevance to mammary tumor suppression. Studies in a variety of rat mammary tumor models have demonstrated that indomethacin protected animals by reducing the incidence and size of tumors [9-12]. This action could not be attributed to the anti-inflammatory effects of indomethacin since other anti-inflammatory drugs (salicylates, carprofen) had no protective effect in parallel experiments [11]. It is well established that the mechanisms underlying mammary development under physiologic and pathologic stimuli involve nuclear hormone receptors and their ligands. For example, the estrogen receptor is frequently mutated in human breast tumors and the estrogenic antagonist, tamoxifen, is commonly used as a chemotherapeutic agent following tumor resection. Based on these findings, we have undertaken studies to determine the expression profile of the PPAR genes in the rodent mammary gland in response to physiologic and pathologic stimuli.

BODY

Experimental methods, assumptions and procedures:

RNA analysis: Total RNA was prepared from 6-10 week old Balb/c female mouse mammary glands (virgin, pregnant, lactating or post-partum) according to published methods [13]. Northern blots were run with 10 µg per lane and hybridized with cDNA probes for PPAR α , PPAR β/δ , PPAR γ , and actin as previously described [6]. The relative levels of PPAR γ 1 and PPAR γ 2 were compared by quantitative PCR using isoform specific oligonucleotide primers listed below:

PPAR γ 1 Oligo #1F: TGTGTGACAGGAAACAGCTATGACCATG
PPAR γ 1 Oligo #1R: ATGCAGGTTCGTAAAACGACGGCCAGT
PPAR γ 1 Oligo #2F: TTTGAGCTCTTCTGACAGGACTGTGTGACAG
PPAR γ 1 Oligo #2R: TTTGAGACTCATAAGGTGGAGATGCAGGTT
PPAR γ 2 Oligo #1F: TGAAACCTCTGGAAACAGCTATGACCAT
PPAR γ 2 Oligo #1R: ATGCAGGTTCGTAAAAGCGACGGCCAGT
PPAR γ 2 Oligo #2F: TTTGAGCTCGCTGTTATGGGTGAAACTCTG
PPAR γ 2 Oligo #2R: TTTGAGCTCATAAGGTGGAGATGCAGGTT

The first reaction was conducted with primer sets #1F and #1R with pBluescript SKII as template to generate a 246 bp product. These products then served as template for a second reaction using primer sets #2F and #2R to generate a final 287 bp product. Reactions were performed using a Perkin Elmer Cetus DNA Thermal Cycler for 35 cycles under the following conditions: 94°, 45 sec; 55°, 45 sec; 72°, 2 min. The final 287 bp products were purified on a non-denaturing acrylamide gel, their concentration determined by densitometry on an ethidium bromide stained analytical gel with a Stratagene Eagle Eye Video Imager system (San Diego CA), and used in competitive PCR reactions. Reactions were performed with serial ten-fold dilutions of competitor DNA fragment ranging from 25 pg to 0.025 fg of DNA in 50 µl volumes containing equal quantities of reverse transcribed virgin mammary gland cDNA (equivalent to 0.7 µg total RNA per reaction), 0.04 OD₂₆₀ units of oligos #2F and #2R, 1 X reaction buffer (Promega, Madison WI), 1.5 mM MgCl₂ and 200 µM dNTP. Reactions were analyzed on 6% nondenaturing acrylamide gels stained with ethidium bromide.

Immunohistochemistry: Tissues from virgin, pregnant or lactating mice were fixed in phosphate buffered saline containing 10% formalin and paraffin embedded. Tissues were sectioned (5 µm thick) onto coated slides (Superfrost Plus, Fisher Scientific, Dallas TX), deparaffinized and the antigen unmasked by microwave treatment in 10 mM citrate buffer pH 6.0. Immunohistochemistry was performed with an affinity purified goat polyclonal antibody prepared against the C terminal peptide of the murine PPAR γ protein [6]. Tissues were incubated with preimmune goat antibody or the affinity purified goat anti-murine PPAR γ antibody for 30 minutes. Additional control experiments were performed with the anti-murine PPAR γ antibody incubated in the presence of the multivalent antigenic peptide as a competitor. The primary goat antibodies were detected with an anti-goat avidin-biotin-horseradish peroxidase coupled reagent (Santa Cruz Biotechnology, Santa Cruz CA). Slides were counter-stained with methyl green or hematoxylin and eosin.

Treatment with DMBA: Virgin 55 day old Sprague Dawley rats (Harlan Sprague Dawley Labs, Indianapolis IN) were exposed to 20 mg DMBA (Sigma Chemical Co, St. Louis MO) suspended in 1 ml of corn oil by gavage feeding [14]. After 16 weeks, mammary glands were harvested, fixed in phosphate buffered formalin and paraffin embedded prior to immunohistochemical analysis as described above. The histologic grade of tumors was assigned based on the criteria of Russo et al [15].

In situ mRNA hybridization: Fresh frozen murine mammary and adipose tissues were sectioned using a cryostat and hybridized with digoxigenin- labeled PPAR cDNA probes. Probes were localized with enzyme-tagged anti-digoxigenin antibodies.

Results and discussion:

The initial experiments have set out to determine how PPAR genes changed in response to physiologic events (Appendix, Page 11, Bottom). Based on northern blots, the mRNA levels of PPAR α and PPAR γ were abundant in virgin mice but declined during pregnancy and lactation. Levels increased in the involuted mammary glands of mice 2 weeks after the cessation of lactation (Nonlact-pp) but did not return completely to the virgin baseline. In contrast, the PPAR β/δ mRNA was constitutively expressed at low levels under all conditions. The blots were hybridized with actin as a control; actin mRNA sizes are known to change during lactation in the mammary gland. Ethidium bromide staining confirmed that the ribosomal RNA was intact in all lanes and that loading was equivalent between lanes (not shown). Two explanations may explain the reduced levels of PPAR α and PPAR γ mRNA in the pregnant and lactating mammary gland. First, the adipocyte stromal cells may be the sole source of the PPAR mRNAs and, as adipocyte cell numbers in the mammary gland are reduced during the epithelial proliferation, the PPAR mRNA levels fall. Alternatively, both adipocyte in the stroma and epithelial cells may express PPAR mRNAs in the virgin mammary gland and these levels are reduced during pregnancy and lactation in response to hormonal cues.

The PPAR γ mRNA can be found as two isoforms reflecting alternative splicing; PPAR γ 1 (1.8 kb) and PPAR γ 2 (2.1 kb) [16]. Since this difference in size cannot be easily distinguished on northern blots, quantitative PCR was used (Appendix, Page 11, Top). Analyses were conducted with cDNA prepared from virgin mammary glands in the presence of serial 10-fold dilutions of specific PPAR γ 1 or PPAR γ 2 competitors (Lanes A-G). When the concentration of native (N) and competitor (C) templates in each reaction were equal, their PCR products displayed equal signal intensity. These analyses determined that PPAR γ 2 mRNA was 10-fold more abundant than PPAR γ 1 mRNA in the mammary gland. This is consistent with previous studies which have identified PPAR γ 2 as the predominant PPAR γ isoform in adipose tissues [3].

This laboratory had previously developed an affinity purified, polyclonal goat antibody directed against the C-terminal peptide of the murine PPAR γ protein [6]; unpublished studies have determined that the antibody will cross react with the PPAR α but not PPAR β/δ proteins based. Histochemical analyses with this reagent examined the levels of PPAR α and PPAR γ immunoreactive proteins in the virgin, pregnant and lactating murine mammary gland (Appendix

Page 12). The pre-immune antibody (Pre) did not immunostain any of the murine tissues (Appendix, Page 12). Immunoreactivity with the anti-PPAR γ (α -PPAR) was detected in the adipocytes of virgin and pregnant (day 8: P-8, day 17:P-17) mammary glands. However, by day 2 of lactation (L-2), PPAR immunoreactivity was absent in the mammary gland adipocytes. In contrast, the epithelial cells of the mammary gland contained immunoreactive protein under all physiologic conditions. The immunoreactive protein, detected in sections stained with antibody alone (indicated by “-”), was effectively competed away by co-incubation in the presence of the peptide antigen (indicated by “+”) (Appendix, Page 13). The immunoreactive protein was most abundant in the cell cytoplasm. Presumably, transcription factors like the PPAR nuclear hormone receptors are found in the nucleus and fixation methods may account for the high levels observed in the cytoplasm. Additional analyses at higher magnification will be required to document nuclear localization of the immunoreactive protein. Studies are underway to examine the expression profile of the estrogen receptor in these tissues.

The anti-PPAR γ antibody has been used to examine mammary tumor specimens from Sprague Dawley rats exposed to DMBA (Appendix, Page 13-14). Both benign (fibroadenoma:F) and malignant (papillary:P, comedo:C, tubular:T) tissue diagnoses have been observed. The level of immunoreactive PPAR proteins was reduced in the adipocytes and epithelial cells of the various tumors as compared to non-malignant tissues (N) obtained distal to the tumor specimens. Studies are underway on a panel of mammary tumor specimens using immunohistochemical methods.

Preliminary *in situ* hybridization studies with the PPAR cDNAs have not been successful. To date, studies have only been conducted with fresh frozen tissues and difficulties can be traced to the fatty nature of the mammary gland. It will be important to repeat these studies with paraffin embedded tissues. Paraffin sections will preserve the architecture better and will be more easily manipulated during the hybridization procedure.

Recommendations in relation to the Statement of Work:


The project is progressing well within the time-frame outlined in the Statement of Work. Both murine and rat specimens have been collected and data analysis is underway. Further work will be required to improve the *in situ* hybridization technology. This will be a priority during the next year of the proposal.


CONCLUSIONS


These preliminary studies document the presence of PPAR proteins in both the mammary stromal adipocytes and epithelial cells. The expression profile of the PPAR mRNA and proteins does not correlate directly. This pattern has been observed with other genes and may reflect altered stability of the PPAR mRNA and protein within adipocytes during pregnancy and lactation without changes in these levels in epithelial cells. These findings have important implications relating to mammary tumor development. Drugs binding to the PPAR-related nuclear hormone receptors, like the vitamin D and retinoic acid receptors, are known to inhibit mammary tumor progression in rodent models. With previous evidence that PPAR ligands may have a protective effect against mammary tumor development in animal models, this suggests that drugs binding to the PPAR proteins might have value as chemopreventive or chemotherapeutic agents in human breast cancer. As such, they could be valuable adjuvants to existing therapies for this disease.

REFERENCES



1. Levine, J.F. and Stockdale, F.E. 1984. *Exp. Cell Res.* 151:112-122.
2. Levine, J.F. and Stockdale, F.E. 1985. *J. Cell Biol.* 100:1415-1422.
3. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A. I. and Spiegelman, B.M. 1994. *Genes & Dev.* 8:1224-1234.
4. Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M. and Evans, R.M. 1995. *Cell* 83:803-812.
5. Kliewer, S.A., Lenhard, J.M., Willson, T.M., Patel, I., Morris, D.C. and Lehmann, J.M. 1995. *Cell* 83:813-820.
6. Gimble, J.M., Robinson, C.E., Wu, X., Kelly, K.A., Rodriguez, B.R., Kliewer, S.A., Lehmann, J.M. and Morris, D.C. 1996. *Mol. Pharmacol.* 50:1087-1094.
7. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M. and Kliewer, S.A. 1995. *J. Biol. Chem.* 270:12953-12956.
8. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M. and Kliewer, S.A. 1997. *J. Biol. Chem.* 272:3406-3410.
9. Kollmorgen, G.M., King, M.M., Kosanke, S.D. and Do, C. 1983. *Cancer Res.* 43:4714-4719.
10. Carter, C.A., Milholland, R.J., Shea, W. and Ip, M.M. 1983. *Cancer Res.* 43:3559-3562.
11. Carter, C.A., Ip, M.M. and Ip, C. 1989. *Carcinogenesis* 10:1369-1374.
12. McCormick, D.L., Madigan, M.J. and Moon, R.C. 1985. *Cancer Res.* 45:1803-1808.
13. Chomczynski, P. and Sacchi, N. 1987. *Anal. Biochem.* 162:156-159.
14. Hollingsworth, A.B., Lerner, M.R., Lightfoot, S.A., Wilkerson, K.B., Hanas, J.S., McCay, P.B. and Brackett, D.J. In press, *Breast Canc. Res. & Treatment*.
15. Russo, J., Russo, I.H., Rogers, A.E., Van Zwieten, M.J. and Gusterson, B. in Pathology of Laboratory Animals: Vol. 1. Tumors of the Rat. V. Turosov, U. Mohr (eds.). Pgs. 47-78.
16. Zhu, Y., Qi, C., Korenberg, J.R., Chen, X.-N., Noya, D., Rao, N.S. and Reddy, J.K. 1995. *Proc. Natl. Acad. Sci. USA* 92:7921-7925.









T



C








N



Pre

 α PPAR

P**F****N****Pre** **α PPAR**